RESUMEN
OBJECTIVE: To compare the 12-month effects of continuous glucose monitoring (CGM) versus blood glucose monitoring (BGM) in adults with insulin-treated type 2 diabetes. RESEARCH DESIGN AND METHODS: This is a single-center, parallel, open-label, randomized controlled trial including adults with inadequately controlled, insulin-treated type 2 diabetes from the outpatient clinic at Steno Diabetes Center Copenhagen, Denmark. Inclusion criteria were ≥18 years of age, insulin-treated type 2 diabetes, and HbA1c ≥7.5% (58 mmol/mol). Participants were randomly assigned (1:1) to 12 months of either CGM or BGM. All participants received a diabetes self-management education course and were followed by their usual health care providers. Primary outcome was between-group differences in change in time in range (TIR) 3.9-10.0 mmol/L, assessed at baseline, after 6 and 12 months by blinded CGM. The prespecified secondary outcomes were differences in change in several other glycemic, metabolic, and participant-reported outcomes. RESULTS: The 76 participants had a median baseline HbA1c of 8.3 (7.8, 9.1)% (67 [62-76] mmol/mol), and 61.8% were male. Compared with BGM, CGM usage was associated with significantly greater improvements in TIR (between-group difference 15.2%, 95% CI 4.6; 25.9), HbA1c (-0.9%, -1.4; -0.3 [-9.4 mmol/mol, -15.2; -3.5]), total daily insulin dose (-10.6 units/day, -19.9; -1.3), weight (-3.3 kg, -5.5; -1.1), and BMI (-1.1 kg/m2, -1.8; -0.3) and greater self-rated diabetes-related health, well-being, satisfaction, and health behavior. CONCLUSIONS: In adults with inadequately controlled insulin-treated type 2 diabetes, the 12-month impact of CGM was superior to BGM in improving glucose control and other crucial health parameters. The findings support the use of CGM in the insulin-treated subgroup of type 2 diabetes.
Asunto(s)
Diabetes Mellitus Tipo 1 , Diabetes Mellitus Tipo 2 , Adulto , Humanos , Masculino , Femenino , Insulina/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Glucemia/metabolismo , Automonitorización de la Glucosa Sanguínea , Hemoglobina Glucada , Monitoreo Continuo de Glucosa , Insulina Regular Humana/uso terapéutico , Hipoglucemiantes/uso terapéuticoRESUMEN
Background: This study aims to examine quality of diabetes care in persons with type 2 diabetes with and without severe mental illness (SMI). Methods: In a nationwide prospective register-based study, we followed persons with type 2 diabetes in Denmark with and without SMI including schizophrenia, bipolar disorder, or major depression. Quality of care was measured as receipt of care (hemoglobin A1c, low-density lipoprotein-cholesterol and urine albumin creatinine ratio assessment and eye and foot screening) and achievement of treatment targets between 2015 and 2019. Quality of care was compared in persons with and without SMI using generalized linear mixed models adjusted for key confounders. Findings: We included 216,537 persons with type 2 diabetes. At entry 16,874 (8%) had SMI. SMI was associated with lower odds of receiving care, with the most pronounced difference in urine albumin creatinine ratio assessment and eye screening (OR: 0.55, 95% CI: 0.53-0.58 and OR: 0.37 95% CI: 0.32-0.42, respectively). Among those with an assessment, we found that SMI was associated with higher achievement of recommended hemoglobin A1c levels and lower achievement of recommended low-density lipoprotein-cholesterol levels. Achievement of recommended low-density lipoprotein-cholesterol levels was similar in persons with versus without schizophrenia. Interpretation: Compared to persons without SMI, persons with SMI were less likely to receive process of care, with the most pronounced differences in urine albumin creatinine ratio assessment and eye screening. Funding: This study was funded by Steno Diabetes Center Copenhagen through an unrestricted grant from Novo Nordisk Foundation.
RESUMEN
OBJECTIVE: To investigate the efficacy and safety of dasiglucagon, a novel stable glucagon analog in a liquid formulation, in Roux-en-Y gastric bypass (RYGB)-operated individuals suffering from postbariatric hypoglycemia (PBH). RESEARCH DESIGN AND METHODS: In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring-verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80 µg or 200 µg dasiglucagon. RESULTS: Compared with placebo, treatment with both 80 and 200 µg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L [mean ± SEM]; 80 µg dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 µg dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.0 min (P = 0.030 and P = 0.008). CONCLUSIONS: Single-dose administration of dasiglucagon effectively mitigated postprandial hypoglycemia.
Asunto(s)
Derivación Gástrica , Hipoglucemia , Glucemia , Automonitorización de la Glucosa Sanguínea , Estudios Cruzados , Método Doble Ciego , Derivación Gástrica/efectos adversos , Glucagón/análogos & derivados , Humanos , Hipoglucemia/tratamiento farmacológico , Hipoglucemia/etiología , Hipoglucemia/prevención & control , Insulina/uso terapéuticoRESUMEN
BACKGROUND: Postbariatric hypoglycemia (PBH) is a potentially serious complication after Roux-en-Y gastric bypass (RYGB), and impaired counterregulatory hormone responses have been suggested to contribute to the condition. OBJECTIVES: We evaluated counterregulatory responses during postprandial hypoglycemia in individuals with PBH who underwent RYGB. SETTING: University hospital. METHODS: Eleven women with documented PBH who had RYGB underwent a baseline liquid mixed meal test (MMT) followed by 5 MMTs preceded by treatment with (1) acarbose 50 mg, (2) sitagliptin 100 mg, (3) verapamil 120 mg, (4) liraglutide 1.2 mg, and (5) pasireotide 300 µg. Blood was collected at fixed time intervals. Plasma and serum were analyzed for glucose, insulin, glucagon, epinephrine, norepinephrine, pancreatic polypeptide (PP), and cortisol. RESULTS: During the baseline MMT, participants had nadir blood glucose concentrations of 3.3 ± .2 mmol/L. At the time of nadir glucose, there was a small but significant increase in plasma glucagon. Plasma epinephrine concentrations were not increased at nadir glucose but were significantly elevated by the end of the MMT. There were no changes in norepinephrine, PP, and cortisol concentrations in response to hypoglycemia. After treatment with sitagliptin, 8 individuals had glucose nadirs <3.2 mmol/L (versus 4 individuals at baseline), and significant increases in glucagon, PP, and cortisol responses were observed. CONCLUSIONS: In response to postprandial hypoglycemia, individuals with PBH who underwent RYGB only had minor increases in counterregulatory hormones, while larger hormone responses occurred when glucose levels were lowered during treatment with sitagliptin. The glycemic threshold for counterregulatory activation could be altered in individuals with PBH, possibly explained by recurrent hypoglycemia.
Asunto(s)
Derivación Gástrica , Hipoglucemia , Obesidad Mórbida , Glucemia , Femenino , Derivación Gástrica/efectos adversos , Humanos , Hipoglucemia/etiología , Insulina , Obesidad Mórbida/cirugíaRESUMEN
BACKGROUND: Early dumping and post-bariatric hypoglycemia (PBH) are often addressed as two separate postprandial complications after Roux-en-Y gastric bypass (RYGB). The aim of the study was to evaluate the occurrence of early dumping in RYGB-operated individuals with PBH with and without treatment intervention. METHODS: Eleven RYGB-operated women with documented PBH each underwent a baseline liquid mixed meal test (MMT) followed by five MMTs preceded by treatment with: acarbose 50 mg for 1 week, sitagliptin 100 mg for 1 week, verapamil 120 mg for 1 week, liraglutide 1.2 mg for 3 weeks, and pasireotide 300 µg as a single dose. Repetitive venous blood sampling and continuous electrocardiogram recordings were performed at fasting and during a 3-h postprandial period. RESULTS: During the baseline MMT, there was a significant increase in HR (from 65 ± 2 to 90 ± 4 bpm, p < 0.0001) within 30 min after meal intake, while hypoglycemia occurred in the later postprandial period. The HR increase was accompanied by significant increases in serum albumin, plasma norepinephrine, blood glucose, serum insulin, and plasma GLP-1 concentrations. The postprandial HR changes were positively correlated with the changes in insulin and GLP-1 concentrations. Treatment with acarbose and pasireotide both reduced HR, plasma norepinephrine, and serum insulin, and pasireotide also decreased plasma GLP-1. CONCLUSIONS: RYGB-operated individuals with PBH also have large early postprandial HR increases, hemoconcentration, and sympathetic activation, consistent with early dumping. Moreover, hormone excursions associated with PBH appear to be related to measures of early dumping, suggesting a causal relationship between early dumping and PBH. TRIAL REGISTRATION: NCT02527993.
Asunto(s)
Derivación Gástrica , Hipoglucemia , Obesidad Mórbida , Glucemia , Femenino , Derivación Gástrica/efectos adversos , Péptido 1 Similar al Glucagón , Humanos , Hipoglucemia/etiología , Insulina , Obesidad Mórbida/cirugía , Periodo PosprandialRESUMEN
Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 µg, 150 µg, and 300 µg) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 µg dose seems sufficient to prevent hypoglycemia.
Asunto(s)
Derivación Gástrica , Hipoglucemia , Obesidad Mórbida , Glucemia , Derivación Gástrica/efectos adversos , Humanos , Hipoglucemia/prevención & control , Insulina , Obesidad Mórbida/cirugía , Somatostatina/análogos & derivadosRESUMEN
BACKGROUND: The prevalence of metabolically healthy obese (MHO) subjects among morbidly obese subjects is poorly described. AIM: To describe the prevalence of metabolically healthy subjects in a group of morbidly obese referred for bariatric surgery. METHODS: Descriptive cross-sectional study, 1209 subjects (825 women/384 men) mean body mass index (BMI) of 45.6 (range: 35-72.6) kg/m2 and mean age of 42.9 (range: 18-72) years were included. Metabolically unhealthy obese subjects had at least two metabolic risk factors: systolic blood pressure >130 mmHg or diastolic blood pressure >85 mmHg or use of antihypertensive medication, diagnosed diabetes with a HbA1c >6.5% (>48 mmol/mol) or use of antidiabetic medication, high plasma triglycerides or low plasma high-density lipoprotein, or use of lipid-lowering medication. MHO subjects had one or no metabolic risk factors. RESULTS: Thirty-four percent (413/1209) were characterized as MHO subjects. The MHO stage was characterized by female sex, younger age, and lower neck and waist circumferences. The odds ratio of metabolic unhealthy was 1.12 (1.07-1.17, P < 0.001) and 1.02 (1.01-1.04, P < 0002) for every 1 cm increase in neck and waist circumferences, respectively, and 0.94 (0.91-0.97, P < 0.001) for every 1 U increase in BMI and 1.04 (1.03-1.05, P < 0.001) for every 1 year increase in age. CONCLUSIONS: Among severely obese subjects, 34% were classified as having a metabolically healthy state, which was more likely to occur in females, younger individuals and was associated with a lower neck and waist circumferences, younger age, and higher BMI. Whether a group of MHO subjects will remain healthy lifelong is unknown.
Asunto(s)
Estado de Salud , Obesidad Mórbida/metabolismo , Adulto , Factores de Edad , Cirugía Bariátrica , Índice de Masa Corporal , Estudios Transversales , Dinamarca/epidemiología , Diabetes Mellitus/epidemiología , Femenino , Humanos , Hipertensión/complicaciones , Hipertensión/epidemiología , Masculino , Persona de Mediana Edad , Cuello/anatomía & histología , Obesidad Mórbida/epidemiología , Obesidad Mórbida/cirugía , Prevalencia , Factores de Riesgo , Factores Sexuales , Circunferencia de la Cintura , Adulto JovenRESUMEN
The combination of gastric bypass, colectomia, lack of substitution with minerals and vitamins, and alcohol consumption led to severe complications in a 57-year-old man. He was submitted to different hospitals 25 times and seen in polyclinics 39 times with no improvement in symptoms of postprandial neurohypoglycaemia, ortostatic hypotension and pronounced hypocalcaemia. The importance of frequent controls after gastric bypass in centres with specialists knowing the common complications after the operation and the need for nutritionel supplements is hereby emphasised.
Asunto(s)
Consumo de Bebidas Alcohólicas/efectos adversos , Derivación Gástrica/efectos adversos , Hipocalcemia/etiología , Hipoglucemia/etiología , Suplementos Dietéticos , Humanos , Hipocalcemia/prevención & control , Hipoglucemia/prevención & control , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/etiologíaRESUMEN
AIM: To investigate whether Roux-en-Y gastric bypass surgery (RYGB) - an in vivo model for normalisation of hyperglycaemia - improves carotid intima-media thickness (IMT) in patients with type 2 diabetes (T2D)/impaired glucose tolerance (IGT) and normal glucose tolerance (NGT). METHODS: Observational prospective study, 34 obese patients (T2D (n = 14)/IGT (n = 4), and NGT (n = 16)) were investigated before and six and 12months after RYGB. RESULTS: Mean carotid IMT was significantly reduced 12months after RYGB in patients with T2D/IGT (-0.041 mm (95% CI -0.069; -0.012, p = 0.005)) but not in patients with NGT (-0.010 mm (-0.039; 0.020, p = 0.52)). The between-group difference was not significant (p=0.13). Twelve months after RYGB, patients with respectively T2D/IGT and NGT demonstrated changes in weight: -29.9 kg, p<0.001/-30.6 kg, p < 0.001, HbA1c: -0.7%, p < 0.001/-0.1%, p = 0.33, systolic blood pressure: -2 mmHg, p = 0.68/-10 mmHg, p = 0.01 and diastolic blood pressure: -8 mmHg, p = 0.003/-11 mmHg, p < 0.001. 80% of T2D patients terminated antihyperglycaemic medication. CONCLUSION: Mean carotid IMT was significantly reduced 12months after RYGB in patients with T2D/IGT which provides evidence to support that the earliest atherosclerotic changes in the arterial wall are reversible. Although numerically different from the changes observed in patients with NGT, the between-group difference was not statistically significant.
Asunto(s)
Grosor Intima-Media Carotídeo , Diabetes Mellitus Tipo 2/complicaciones , Angiopatías Diabéticas/prevención & control , Regulación hacia Abajo , Derivación Gástrica , Intolerancia a la Glucosa/complicaciones , Obesidad Mórbida/cirugía , Adolescente , Adulto , Índice de Masa Corporal , Dinamarca/epidemiología , Diabetes Mellitus Tipo 2/sangre , Angiopatías Diabéticas/complicaciones , Angiopatías Diabéticas/diagnóstico por imagen , Angiopatías Diabéticas/epidemiología , Femenino , Intolerancia a la Glucosa/sangre , Hemoglobina Glucada/análisis , Humanos , Hiperglucemia/prevención & control , Hipertensión/complicaciones , Hipertensión/epidemiología , Hipertensión/prevención & control , Masculino , Persona de Mediana Edad , Obesidad Mórbida/sangre , Obesidad Mórbida/complicaciones , Factores de Riesgo , Enfermedades Vasculares/complicaciones , Enfermedades Vasculares/diagnóstico por imagen , Enfermedades Vasculares/epidemiología , Enfermedades Vasculares/prevención & control , Pérdida de Peso , Adulto JovenRESUMEN
Roux-en-Y gastric bypass (RYGB) improves glycemic control within days after surgery, and changes in insulin sensitivity and ß-cell function are likely to be involved. We studied 10 obese patients with type 2 diabetes (T2D) and 10 obese glucose-tolerant subjects before and 1 week, 3 months, and 1 year after RYGB. Participants were included after a preoperative diet-induced total weight loss of -9.2 ± 1.2%. Hepatic and peripheral insulin sensitivity were assessed using the hyperinsulinemic- euglycemic clamp combined with the glucose tracer technique, and ß-cell function was evaluated in response to an intravenous glucose-glucagon challenge as well as an oral glucose load. Within 1 week, RYGB reduced basal glucose production, improved basal hepatic insulin sensitivity, and increased insulin clearance, highlighting the liver as an important organ responsible for early effects on glucose metabolism after surgery. Insulin-mediated glucose disposal and suppression of fatty acids did not improve immediately after surgery but increased at 3 months and 1 year; this increase likely was related to the reduction in body weight. Insulin secretion increased after RYGB only in patients with T2D and only in response to oral glucose, underscoring the importance of the changed gut anatomy.
Asunto(s)
Diabetes Mellitus Tipo 2/metabolismo , Resistencia a la Insulina/fisiología , Insulina/metabolismo , Hígado/metabolismo , Obesidad/metabolismo , Adulto , Glucemia/metabolismo , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/cirugía , Femenino , Derivación Gástrica , Técnica de Clampeo de la Glucosa , Humanos , Secreción de Insulina , Células Secretoras de Insulina/metabolismo , Masculino , Persona de Mediana Edad , Obesidad/complicaciones , Obesidad/cirugía , Periodo PosprandialRESUMEN
Experience with Roux-en-Y gastric bypass in patients with type 1 diabetes is very limited, despite an increasing prevalence of obesity also in this population. We describe changes in anthropometric measures, insulin dose, HbA1c, blood pressure, lipid status, and metabolic response to a liquid mixed meal throughout the first year after RYGB in an obese patient with type 1 diabetes. No change in HbA1c was observed, but a 48% reduction in weight-adjusted insulin dose and improvements in cardiovascular risk factors was seen 1 year after surgery. Exaggerated secretions of anorexigenic gut hormones were seen during the meals.
Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Diabetes Mellitus Tipo 1/cirugía , Derivación Gástrica , Células Secretoras de Insulina/citología , Insulina/administración & dosificación , Obesidad Mórbida/cirugía , Adulto , Diabetes Mellitus Tipo 1/sangre , Femenino , Humanos , Insulina/sangre , Obesidad Mórbida/sangre , Factores de RiesgoRESUMEN
AIMS/HYPOTHESIS: Roux-en-Y gastric bypass (RYGB) improves glycaemic control in part by increasing postprandial insulin secretion through exaggerated glucagon-like peptide (GLP)-1 release. However, it is unknown whether islet cell responsiveness to i.v. glucose, non-glucose (arginine) and incretin hormones, including GLP-1, is altered. METHODS: Eleven severely obese glucose-tolerant individuals underwent three hyperglycaemic clamps with arginine bolus and co-infusion of either GLP-1, glucose-dependent insulinotropic polypeptide (GIP) or saline before, and at 1 week and 3 months after RYGB. In addition, an OGTT was performed before and 3 months after surgery. RESULTS: After RYGB, insulin sensitivity improved at 1 week and 3 months, while insulin stimulation and glucagon suppression in response to the clamp with saline co-infusion were largely unaltered. The influence of i.v. GLP-1 and GIP on insulin and glucagon secretion was also unchanged postoperatively. In response to the postoperative OGTT at 3 months, insulin and GLP-1, but not GIP, secretion increased. Furthermore, the glucose profile during the OGTT was altered, with a substantial reduction in 2 h plasma glucose and a paradoxical hypersecretion of glucagon. CONCLUSIONS/INTERPRETATION: After RYGB, insulin hypersecretion is linked to the oral, but not the i.v., route of administration and is associated with exaggerated release and preserved insulinotropic action of GLP-1, while both the secretion and action of GIP are unchanged. The results highlight the importance of increased GLP-1 secretion for improving postoperative glucose metabolism. TRIAL REGISTRATION: ClinicalTrials.gov NCT01559779.
Asunto(s)
Glucemia/metabolismo , Derivación Gástrica , Polipéptido Inhibidor Gástrico/metabolismo , Péptido 1 Similar al Glucagón/metabolismo , Insulina/metabolismo , Obesidad Mórbida/metabolismo , Páncreas/metabolismo , Fragmentos de Péptidos/metabolismo , Adulto , Femenino , Glucagón/metabolismo , Técnica de Clampeo de la Glucosa/métodos , Prueba de Tolerancia a la Glucosa , Humanos , Hiperglucemia/metabolismo , Resistencia a la Insulina , Secreción de Insulina , Masculino , Obesidad Mórbida/fisiopatología , Obesidad Mórbida/cirugía , Periodo Posprandial , Resultado del TratamientoRESUMEN
AIMS/HYPOTHESIS: Roux-en-Y gastric bypass surgery (RYGB) improves glucose tolerance in patients with type 2 diabetes, but also changes the glucose profile in response to a meal in glucose-tolerant individuals. We hypothesised that the driving force for the changed postprandial glucose profiles after RYGB is rapid entry of glucose into the systemic circulation due to modified gastrointestinal anatomy, causing hypersecretion of insulin and other hormones influencing glucose disappearance and endogenous glucose production. METHODS: We determined glucose absorption and metabolism and the rate of lipolysis before and 3 months after RYGB in obese glucose-tolerant individuals using the double-tracer technique during a mixed meal. RESULTS: After RYGB, the postprandial plasma glucose profile changed, with a higher peak glucose concentration followed by a faster return to lower than basal levels. These changes were brought about by changes in glucose kinetics: (1) a more rapid appearance of ingested glucose in the systemic circulation, and a concomitant increase in insulin and glucagon-like peptide-1 secretion; (2) postprandial glucose disappearance was maintained at a high rate for a longer time after RYGB. Endogenous glucose production was similar before and after surgery. Postoperative glucagon secretion increased and showed a biphasic response after RYGB. Adipose tissue basal rate of lipolysis was higher after RYGB. CONCLUSIONS/INTERPRETATION: A rapid rate of absorption of ingested glucose into the systemic circulation, followed by increased insulin secretion and glucose disappearance appears to drive the changes in the glucose profile observed after RYGB, while endogenous glucose production remains unchanged. TRIAL REGISTRATION: ClinicalTrials.gov NCT01559792. FUNDING: The study was part of the UNIK program: Food, Fitness & Pharma for Health and Disease (see www.foodfitnesspharma.ku.dk ). Funding was received from the Novo Nordisk foundation and the Strategic Research Counsel for the Capital Area and Danish Research Agency. The primary investigator received a PhD scholarship from the University of Copenhagen, which was one-third funded by Novo Nordisk.
Asunto(s)
Derivación Gástrica , Absorciometría de Fotón , Índice de Masa Corporal , Femenino , Glucosa/metabolismo , Humanos , MasculinoRESUMEN
ß-Cell function improves in patients with type 2 diabetes in response to an oral glucose stimulus after Roux-en-Y gastric bypass (RYGB) surgery. This has been linked to the exaggerated secretion of glucagon-like peptide 1 (GLP-1), but causality has not been established. The aim of this study was to investigate the role of GLP-1 in improving ß-cell function and glucose tolerance and regulating glucagon release after RYGB using exendin(9-39) (Ex-9), a GLP-1 receptor (GLP-1R)-specific antagonist. Nine patients with type 2 diabetes were examined before and 1 week and 3 months after surgery. Each visit consisted of two experimental days, allowing a meal test with randomized infusion of saline or Ex-9. After RYGB, glucose tolerance improved, ß-cell glucose sensitivity (ß-GS) doubled, the GLP-1 response greatly increased, and glucagon secretion was augmented. GLP-1R blockade did not affect ß-cell function or meal-induced glucagon release before the operation but did impair glucose tolerance. After RYGB, ß-GS decreased to preoperative levels, glucagon secretion increased, and glucose tolerance was impaired by Ex-9 infusion. Thus, the exaggerated effect of GLP-1 after RYGB is of major importance for the improvement in ß-cell function, control of glucagon release, and glucose tolerance in patients with type 2 diabetes.
Asunto(s)
Diabetes Mellitus Tipo 2/metabolismo , Derivación Gástrica , Péptido 1 Similar al Glucagón/metabolismo , Células Secretoras de Insulina/metabolismo , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Ayuno/sangre , Femenino , Vaciamiento Gástrico/efectos de los fármacos , Polipéptido Inhibidor Gástrico , Glucagón/metabolismo , Receptor del Péptido 1 Similar al Glucagón , Humanos , Resistencia a la Insulina/fisiología , Células Secretoras de Insulina/efectos de los fármacos , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/farmacología , Receptores de Glucagón/antagonistas & inhibidoresRESUMEN
CONTEXT: Roux-en-Y gastric bypass (RYGB) improves glucose tolerance and ameliorates fasting hyperinsulinemia within days after surgery. Improvements in hepatic insulin sensitivity and insulin clearance could contribute importantly to these effects. OBJECTIVE: The objective of the investigation was to study changes in insulin clearance after RYGB. DESIGN: This was a prospective study of fasting hepatic insulin clearance and, in a subgroup of patients, postprandial insulin clearance after a meal test before and 1 week, 3 months, and 1 year after RYGB. SETTING: The study was conducted at Hvidovre Hospital (Hvidovre, Denmark). PATIENTS: Patients included 2 groups of obese RYGB-patients: 1) type 2 diabetes (T2D) group: 32 patients with T2D (meal test, n = 13), 2) normal glucose tolerance (NGT) group: 32 patients with NGT (meal test, n = 12). INTERVENTION: The intervention was RYGB. MAIN OUTCOME MEASURE: Fasting hepatic insulin clearance (fasting C-peptide/fasting insulin). Postprandial insulin clearance (incremental areas under the curve of insulin secretion rates/incremental areas under the curve of insulin). RESULTS: Fasting hepatic insulin clearance increased after 1 week (P < .01) and further at 3 months (P < .01), remaining elevated 1 year postoperatively (P < .01) with no difference between the T2D and NGT groups. Postprandial insulin clearance changed only in the T2D group with an increase at 1 week (P < .01) that was maintained at 3 months (P = .06) and 1 year (P < .01). CONCLUSIONS: RYGB increases insulin clearance within 1 week after surgery, highlighting the liver as a key organ involved in the early beneficial effect on glucose metabolism. Postprandial insulin secretion may be underestimated postoperatively in patients with type 2 diabetes when evaluated by peripheral insulin concentrations instead of insulin secretion rates or C-peptide.
Asunto(s)
Diabetes Mellitus Tipo 2/metabolismo , Derivación Gástrica , Insulina/metabolismo , Hígado/metabolismo , Péptido C/sangre , Ácidos Grasos no Esterificados/sangre , Femenino , Humanos , Masculino , Tasa de Depuración Metabólica , Estudios ProspectivosRESUMEN
OBJECTIVE: To examine after gastric bypass the effect of peroral versus gastroduodenal feeding on glucose metabolism. RESEARCH DESIGN AND METHODS: A type 2 diabetic patient was examined on 2 consecutive days 5 weeks after gastric bypass. A standard liquid meal was given on the first day into the bypassed gastric remnant and on the second day perorally. Plasma glucose, insulin, C-peptide, glucagon, incretin hormones, peptide YY, and free fatty acids were measured. RESULTS: Peroral feeding reduced 2-h postprandial plasma glucose (7.8 vs. 11.1 mmol/l) and incremental area under the glucose curve (iAUC) (0.33 vs. 0.49 mmol . l(-1) . min(-1)) compared with gastroduodenal feeding. beta-Cell function (iAUC(Cpeptide/Glu)) was more than twofold improved during peroral feeding, and the glucagon-like peptide (GLP)-1 response increased nearly fivefold. CONCLUSIONS: Improvement in postprandial glucose metabolism after gastric bypass is an immediate and direct consequence of the gastrointestinal rearrangement, associated with exaggerated GLP-1 release and independent of changes in insulin sensitivity, weight loss, and caloric restriction.